{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:34:55Z","timestamp":1794573295210,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"MEXT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ym0126809, JP24ym0126809"],"award-info":[{"award-number":["JP23ym0126809, JP24ym0126809"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23K18313, 24K02518, 23KK0153, 24K22144, 23K19505, 24K19992, 25H01060"],"award-info":[{"award-number":["23K18313, 24K02518, 23KK0153, 24K22144, 23K19505, 24K19992, 25H01060"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007802","name":"Institute for Fermentation, Osaka","doi-asserted-by":"publisher","award":["G2024-3-006"],"award-info":[{"award-number":["G2024-3-006"]}],"id":[{"id":"10.13039\/100007802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31128-5","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:50:01Z","timestamp":1765335001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models"],"prefix":"10.1038","volume":"16","author":[{"given":"Sikun","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Tatekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Arao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"31128_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091636","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi, H. & Miyazaki, M. Heterocellular adhesion in cancer invasion and metastasis: interactions between cancer cells and cancer-associated fibroblasts. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16091636 (2024).","journal-title":"Cancers (Basel)"},{"key":"31128_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421\u2013433. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.009 (2023).","journal-title":"Cancer Cell"},{"key":"31128_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v9i1.647","volume":"9","author":"MF Giraudo","year":"2024","unstructured":"Giraudo, M. F., Jackson, Z., Das, I., Abiona, O. M. & Wald, D. N. Chimeric antigen receptor (CAR)-T cell therapy for non-hodgkin\u2019s lymphoma. Pathog. Immun. 9, 1\u201317. https:\/\/doi.org\/10.20411\/pai.v9i1.647 (2024).","journal-title":"Pathog. Immun."},{"key":"31128_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094996","author":"R Pereira","year":"2024","unstructured":"Pereira, R. & Bergantim, R. An assessment of the effectiveness and safety of chimeric antigen receptor T-cell therapy in multiple myeloma patients with relapsed or refractory disease: a systematic review and meta-analysis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25094996 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"31128_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N. & June, C. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005 (2025).","journal-title":"Mol. Ther."},{"key":"31128_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31128_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115331","volume":"210","author":"SC Adams","year":"2024","unstructured":"Adams, S. C. et al. Immunotherapies for locally aggressive cancers. Adv. Drug Deliv. Rev. 210, 115331. https:\/\/doi.org\/10.1016\/j.addr.2024.115331 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"31128_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753 (2021).","journal-title":"Pharmacol. Ther."},{"key":"31128_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","volume":"6","author":"W Ceelen","year":"2020","unstructured":"Ceelen, W., Ramsay, R. G., Narasimhan, V., Heriot, A. G. & De Wever, O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer 6, 236\u2013246. https:\/\/doi.org\/10.1016\/j.trecan.2019.12.008 (2020).","journal-title":"Trends Cancer"},{"key":"31128_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/hep.0000000000000869","volume":"80","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Comprehensive molecular classification predicted microenvironment profiles and therapy response for HCC. Hepatology 80, 536\u2013551. https:\/\/doi.org\/10.1097\/hep.0000000000000869 (2024).","journal-title":"Hepatology"},{"key":"31128_CR11","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.Can-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L. et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82, 2904\u20132917. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-4141 (2022).","journal-title":"Cancer Res."},{"key":"31128_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang, D., Liu, J., Qian, H. & Zhuang, Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322\u20131332. https:\/\/doi.org\/10.1038\/s12276-023-01013-0 (2023).","journal-title":"Exp. Mol. Med."},{"key":"31128_CR13","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","volume":"29","author":"PK Wan","year":"2021","unstructured":"Wan, P. K., Ryan, A. J. & Seymour, L. W. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol. Ther. 29, 1668\u20131682. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.015 (2021).","journal-title":"Mol. Ther."},{"key":"31128_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol. Cancer 22, 159. https:\/\/doi.org\/10.1186\/s12943-023-01860-5 (2023).","journal-title":"Mol. Cancer"},{"key":"31128_CR15","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.ymthe.2023.08.018","volume":"31","author":"KP Hartmann","year":"2023","unstructured":"Hartmann, K. P. et al. FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment. Mol. Ther. 31, 2914\u20132928. https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.018 (2023).","journal-title":"Mol. Ther."},{"key":"31128_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014 (2023).","journal-title":"Cell"},{"key":"31128_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237469","author":"A Argentiero","year":"2023","unstructured":"Argentiero, A. et al. The complexity of the tumor microenvironment in hepatocellular carcinoma and emerging therapeutic developments. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12237469 (2023).","journal-title":"J. Clin. Med."},{"key":"31128_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030559","author":"AA Lekan","year":"2024","unstructured":"Lekan, A. A. & Weiner, L. M. The role of chemokines in orchestrating the immune response to pancreatic ductal adenocarcinoma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16030559 (2024).","journal-title":"Cancers (Basel)"},{"key":"31128_CR19","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110. https:\/\/doi.org\/10.1038\/s41467-023-40850-5 (2023).","journal-title":"Nat. Commun."},{"key":"31128_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra, Y. & Weeraratna, A. T. Fibroblasts in cancer: unity in heterogeneity. Cell 186, 1580\u20131609. https:\/\/doi.org\/10.1016\/j.cell.2023.03.016 (2023).","journal-title":"Cell"},{"key":"31128_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680. https:\/\/doi.org\/10.1038\/s41568-020-0285-7 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"31128_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali, S., Rahiman, N., Jaafari, M. R. & Arabi, L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv. Transl. Res. 13, 2041\u20132056. https:\/\/doi.org\/10.1007\/s13346-023-01308-9 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"key":"31128_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113678","volume":"382","author":"H Li","year":"2025","unstructured":"Li, H. et al. FAP-targeted delivery of radioiodinated probes: a progressive albumin-driven strategy for tumor theranostics. J. Control Release 382, 113678. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113678 (2025).","journal-title":"J. Control Release"},{"key":"31128_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13402-023-00872-z","volume":"47","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment. Cell Oncol. (Dordr) 47, 361\u2013381. https:\/\/doi.org\/10.1007\/s13402-023-00872-z (2024).","journal-title":"Cell Oncol. (Dordr)"},{"key":"31128_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jconrel.2024.02.014","volume":"367","author":"M Bocci","year":"2024","unstructured":"Bocci, M. et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. J. Control Release 367, 779\u2013790. https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.014 (2024).","journal-title":"J. Control Release"},{"key":"31128_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/cas.16443","volume":"116","author":"M Yamazaki","year":"2025","unstructured":"Yamazaki, M. & Ishimoto, T. Targeting cancer-associated fibroblasts: eliminate or reprogram?. Cancer Sci. 116, 613\u2013621. https:\/\/doi.org\/10.1111\/cas.16443 (2025).","journal-title":"Cancer Sci."},{"key":"31128_CR27","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1111\/cas.16285","volume":"115","author":"S Meng","year":"2024","unstructured":"Meng, S., Hara, T., Miura, Y. & Ishii, H. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors. Cancer Sci. 115, 3532\u20133542. https:\/\/doi.org\/10.1111\/cas.16285 (2024).","journal-title":"Cancer Sci."},{"key":"31128_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jconrel.2024.05.006","volume":"370","author":"Y Sato","year":"2024","unstructured":"Sato, Y., Nakamura, T., Yamada, Y. & Harashima, H. The impact of, and expectations for, lipid nanoparticle technology: from cellular targeting to organelle targeting. J. Control Release 370, 516\u2013527. https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.006 (2024).","journal-title":"J. Control Release"},{"key":"31128_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/s0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204. https:\/\/doi.org\/10.1016\/s0140-6736(23)02444-3 (2024).","journal-title":"Lancet"},{"key":"31128_CR30","doi-asserted-by":"publisher","first-page":"9746","DOI":"10.1021\/acsnano.4c02610","volume":"18","author":"T Unruh","year":"2024","unstructured":"Unruh, T. et al. Mesoscopic structure of lipid nanoparticle formulations for mRNA drug delivery: comirnaty and drug-free dispersions. ACS Nano. 18, 9746\u20139764. https:\/\/doi.org\/10.1021\/acsnano.4c02610 (2024).","journal-title":"ACS Nano."},{"key":"31128_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310168","volume":"36","author":"S Nie","year":"2024","unstructured":"Nie, S., Qin, Y., Ou, L., Chen, X. & Li, L. In Situ reprogramming of immune cells using synthetic nanomaterials. Adv. Mater. 36, e2310168. https:\/\/doi.org\/10.1002\/adma.202310168 (2024).","journal-title":"Adv. Mater."},{"key":"31128_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073119","author":"S Meng","year":"2025","unstructured":"Meng, S. et al. In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms26073119 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"31128_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594 (2022).","journal-title":"Science"},{"key":"31128_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310395","volume":"62","author":"E \u00c1lvarez-Benedicto","year":"2023","unstructured":"\u00c1lvarez-Benedicto, E. et al. Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma. Angew. Chem. Int. Ed. Engl. 62, e202310395. https:\/\/doi.org\/10.1002\/anie.202310395 (2023).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"31128_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley, M. M. et al. In Vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, e2304378. https:\/\/doi.org\/10.1002\/smll.202304378 (2024).","journal-title":"Small"},{"key":"31128_CR36","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels, A., Ho, N. & Buchholz, C. J. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol. Ther. 30, 2401\u20132415. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.018 (2022).","journal-title":"Mol. Ther."},{"key":"31128_CR37","doi-asserted-by":"publisher","first-page":"104659","DOI":"10.1016\/j.isci.2022.104659","volume":"25","author":"R Chijimatsu","year":"2022","unstructured":"Chijimatsu, R. et al. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Science 25, 104659. https:\/\/doi.org\/10.1016\/j.isci.2022.104659 (2022).","journal-title":"Science"},{"key":"31128_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biom14081042","author":"S Mu","year":"2024","unstructured":"Mu, S., Zhao, K., Zhong, S. & Wang, Y. The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder. Biomolecules https:\/\/doi.org\/10.3390\/biom14081042 (2024).","journal-title":"Biomolecules"},{"key":"31128_CR39","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/cas.16152","volume":"115","author":"T Hara","year":"2024","unstructured":"Hara, T. et al. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Cancer Sci. 115, 2360\u20132370. https:\/\/doi.org\/10.1111\/cas.16152 (2024).","journal-title":"Cancer Sci."},{"key":"31128_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115263","volume":"218","author":"JGM Strijker","year":"2025","unstructured":"Strijker, J. G. M. et al. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. Eur. J. Cancer 218, 115263. https:\/\/doi.org\/10.1016\/j.ejca.2025.115263 (2025).","journal-title":"Eur. J. Cancer"},{"key":"31128_CR41","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","volume":"184","author":"LR Johnson","year":"2021","unstructured":"Johnson, L. R. et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell 184, 4981-4995.e4914. https:\/\/doi.org\/10.1016\/j.cell.2021.08.004 (2021).","journal-title":"Cell"},{"key":"31128_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-024-02007-w","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z., Xia, Y., Chen, R., Gao, P. & Duan, S. Unveiling a novel fusion gene enhances CAR T cell therapy for solid tumors. Mol. Cancer 23, 98. https:\/\/doi.org\/10.1186\/s12943-024-02007-w (2024).","journal-title":"Mol. Cancer"},{"key":"31128_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1857","volume":"10","author":"CD Nishimura","year":"2024","unstructured":"Nishimura, C. D. et al. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Sci. Adv. 10, eadk1857. https:\/\/doi.org\/10.1126\/sciadv.adk1857 (2024).","journal-title":"Sci. Adv."},{"key":"31128_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1664","volume":"14","author":"P Leland","year":"2024","unstructured":"Leland, P. et al. Identification and characterisation of novel CAR-T cells to target IL13R\u03b12 positive human glioma in vitro and in vivo. Clin. Transl. Med. 14, e1664. https:\/\/doi.org\/10.1002\/ctm2.1664 (2024).","journal-title":"Clin. Transl. Med."},{"key":"31128_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090725","author":"B Amor\u00f3s-P\u00e9rez","year":"2024","unstructured":"Amor\u00f3s-P\u00e9rez, B., Rivas-Pardo, B., G\u00f3mez, M., Del Moral, J. L. & Mart\u00ednez-Naves, S. E. State of the art in car-t cell therapy for solid tumors: is there a sweeter future?. Cells https:\/\/doi.org\/10.3390\/cells13090725 (2024).","journal-title":"Cells"},{"key":"31128_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084170","author":"J Rojas-Quintero","year":"2024","unstructured":"Rojas-Quintero, J. et al. Car T cells in solid tumors: overcoming obstacles. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25084170 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"31128_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31128_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","author":"JF Bimbo","year":"2025","unstructured":"Bimbo, J. F. et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer https:\/\/doi.org\/10.1136\/jitc-2025-011759 (2025).","journal-title":"J Immunother Cancer"},{"key":"31128_CR49","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.7150\/thno.37198","volume":"9","author":"J Park","year":"2019","unstructured":"Park, J. et al. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics 9, 8073\u20138090. https:\/\/doi.org\/10.7150\/thno.37198 (2019).","journal-title":"Theranostics"},{"key":"31128_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115550","volume":"219","author":"IB Belyaev","year":"2025","unstructured":"Belyaev, I. B., Griaznova, O. Y., Yaremenko, A. V., Deyev, S. M. & Zelepukin, I. V. Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors. Adv. Drug Deliv. Rev. 219, 115550. https:\/\/doi.org\/10.1016\/j.addr.2025.115550 (2025).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"31128_CR51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085. https:\/\/doi.org\/10.1182\/blood.2021010930 (2021).","journal-title":"Blood"},{"key":"31128_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang, M. et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24, 136. https:\/\/doi.org\/10.1186\/s12943-025-02305-x (2025).","journal-title":"Mol Cancer"},{"key":"31128_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.20517\/2394-4722.2022.51","volume":"8","author":"RDS Reena","year":"2022","unstructured":"Reena, R. D. S. et al. Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM). J. Cancer Metastasis Treat. 8, 28. https:\/\/doi.org\/10.20517\/2394-4722.2022.51 (2022).","journal-title":"J. Cancer Metastasis Treat."},{"key":"31128_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019 (2025).","journal-title":"Cancer Cell"},{"key":"31128_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-101320-020220","volume":"42","author":"SN Christo","year":"2024","unstructured":"Christo, S. N., Park, S. L., Mueller, S. N. & Mackay, L. K. The multifaceted role of tissue-resident memory T cells. Annu. Rev. Immunol. 42, 317\u2013345. https:\/\/doi.org\/10.1146\/annurev-immunol-101320-020220 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"31128_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","volume":"23","author":"JM Schenkel","year":"2023","unstructured":"Schenkel, J. M. & Pauken, K. E. Localization, tissue biology and T cell state - implications for cancer immunotherapy. Nat. Rev. Immunol. 23, 807\u2013823. https:\/\/doi.org\/10.1038\/s41577-023-00884-8 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"31128_CR57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy, B. et al. Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41, 585-601.e588. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.004 (2023).","journal-title":"Cancer Cell"},{"key":"31128_CR58","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","volume":"181","author":"S Zaccara","year":"2020","unstructured":"Zaccara, S. & Jaffrey, S. R. A unified model for the function of YTHDF proteins in regulating m(6)A-modified mRNA. Cell 181, 1582-1595.e1518. https:\/\/doi.org\/10.1016\/j.cell.2020.05.012 (2020).","journal-title":"Cell"},{"key":"31128_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14210","volume":"23","author":"X Lu","year":"2024","unstructured":"Lu, X. et al. HIF-1\u03b1-induced expression of the m6A reader YTHDF1 inhibits the ferroptosis of nucleus pulposus cells by promoting SLC7A11 translation. Aging Cell 23, e14210. https:\/\/doi.org\/10.1111\/acel.14210 (2024).","journal-title":"Aging Cell"},{"key":"31128_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-024-03349-7","volume":"24","author":"Y Li","year":"2024","unstructured":"Li, Y., Xiao, Z., Wang, Y., Zhang, D. & Chen, Z. The m6A reader IGF2BP2 promotes esophageal cell carcinoma progression by enhancing EIF4A1 translation. Cancer Cell Int. 24, 162. https:\/\/doi.org\/10.1186\/s12935-024-03349-7 (2024).","journal-title":"Cancer Cell Int."},{"key":"31128_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/biom14050514","author":"J Han","year":"2024","unstructured":"Han, J. et al. Novel insights into the links between n6-methyladenosine and regulated cell death in musculoskeletal diseases. Biomolecules https:\/\/doi.org\/10.3390\/biom14050514 (2024).","journal-title":"Biomolecules"},{"key":"31128_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2826","volume":"10","author":"N Shah","year":"2010","unstructured":"Shah, N. & Sukumar, S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10, 361\u2013371. https:\/\/doi.org\/10.1038\/nrc2826 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"31128_CR63","doi-asserted-by":"publisher","unstructured":"Calvo, R. et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A 97 12776-12781 https:\/\/doi.org\/10.1073\/pnas.97.23.12776 (2000)","DOI":"10.1073\/pnas.97.23.12776"},{"key":"31128_CR64","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1128\/mcb.19.4.3051","volume":"19","author":"WF Shen","year":"1999","unstructured":"Shen, W. F. et al. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol. Cell Biol. 19, 3051\u20133061. https:\/\/doi.org\/10.1128\/mcb.19.4.3051 (1999).","journal-title":"Mol. Cell Biol."},{"key":"31128_CR65","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ccell.2020.03.004","volume":"37","author":"SL Guerra","year":"2020","unstructured":"Guerra, S. L. et al. A deregulated HOX gene axis confers an epigenetic vulnerability in KRAS-mutant lung cancers. Cancer Cell 37, 705-719.e706. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.004 (2020).","journal-title":"Cancer Cell"},{"key":"31128_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106742","volume":"190","author":"A Zinzi","year":"2023","unstructured":"Zinzi, A. et al. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data. Pharmacol. Res. 190, 106742. https:\/\/doi.org\/10.1016\/j.phrs.2023.106742 (2023).","journal-title":"Pharmacol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31128-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31128-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:03:09Z","timestamp":1768345389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31128-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31128"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31128-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Partial institutional endowments were received from Hirotsu Bio Science Inc. (Tokyo, Japan), Kinshu-kai Medical Corporation (Osaka, Japan), Kyowa-kai Medical Corporation (Kawanishi, Hyogo and Osaka, Japan), IDEA Consultants Inc. (Tokyo, Japan), and Unitech Co. Ltd. (Chiba, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animals in this study were cared according to Osaka University\u2019s standards for care and use of laboratory animals, and operation procedures were performed in accordance with protocols approved by the Laboratory Investigation Committee, Osaka University Medical School (Approval No. 04-105-014).All patient-derived tumor tissues used for PDX establishment were purchased from the Central Institute for Experimental Medicine and Life Science. The institute confirmed that all human samples were collected with informed consent from donors and with approval from the appropriate institutional ethics committee, in compliance with all relevant guidelines and regulations. No human participants were directly involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1624"}}